RIL
CLDX icon

Rothschild Investment LLC’s Celldex Therapeutics CLDX Stock Holding History

Rothschild Investment LLC’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.77K Buy
119
+27
+29% +$736 ﹤0.01% 2210
2025
Q4 		$2.5K Buy
92
+2
+2% +$53 ﹤0.01% 2255
2025
Q3 		$2.33K Sell
90
-20
-18% -$463 ﹤0.01% 2136
2025
Q2 		$2.24K Buy
110
+20
+22% +$389 ﹤0.01% 1995
2025
Q1 		$1.63K Sell
90
-15
-14% -$335 ﹤0.01% 2025
2024
Q4 		$2.65K Buy
105
+45
+75% +$1.22K ﹤0.01% 1636
2024
Q3 		$2.04K Buy
60
+35
+140% +$1.33K ﹤0.01% 1716
2024
Q2 		$925 Buy
25
+20
+400% +$755 ﹤0.01% 1701
2024
Q1 		$210 Buy
+5
New +$205 ﹤0.01% 1725

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return